Openbookopenbook
Equity
NONOF
+0.0 · +0.00%
USD · PINK

Novo Nordisk A/S(NONOF) Stock Analysis | Healthcare

USD --+0.00%
Reward68High
Risk25Low
75%Data
Strong 33% profit margin · 30.6% dividend yield · Revenue down 8% YoY
Dividend King
Market Cap:170.19Bn
ⓘ
Reward Rating
68
High
Reward Assessment
75% data coverage
Top 25% of stocksView factors
ⓘ
Risk Rating
25
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NONOF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for NONOF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $54.82.

What is Novo Nordisk A/S?

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

NONOF · Verdict

Solid reward · low risk

NONOF scores well on cash flow and profitability with no major weaknesses flagged in the model.

Based on 88% data coverage

NONOF · Verdict

What’s working & what to watch

Strengths 5

  • Cash flow95/100

    19% free-cash-flow margin

  • Profitability88/100

    33% net margin · 61% ROE

  • Volatility80/100

    Top decile vs peers

  • Valuation73/100

    P/E 13.1× · PEG 4.09

  • Growth67/100

    Rev +20.3% CAGR · earnings +22.6%

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Novo Nordisk A/S?

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 170.19B, and a P/E ratio of 10.5x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (68)

The scoring profile indicates moderate reward potential, with profitability and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

GILDLarge Cap / 181B market cap
Gilead Sciences Inc
Compare
PFELarge Cap / 153B market cap
Pfizer Inc
Compare
BMYLarge Cap / 137B market cap
Bristol-Myers Squibb Company
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap170.19B
P/E Ratio10.5482
Dividend Yield30.58%
Beta0.403
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.